Nabonita Barua, MD
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1881199883
Payments from drug & device makers
Across 14 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$63
- Tandem Diabetes Care, Inc.$59
- Ascensia Diabetes Care US Inc.$43
- Recordati_rare_diseases_inc.$25
- Insulet Corporation$23
- Abbott$22
- plus $112 from 6 others
What the payments were for
- Food & beverage$33496%
- Education$144%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 2 | $63 |
| Tandem Diabetes Care, Inc. | 1 | $59 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Insulet Corporation | 1 | $23 |
| Abbott | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Medtronic | 1 | $16 |
| Amgen | 1 | $14 |
How this compares
$348 in reported general payments places this provider in the 35th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 56 | $50,109 |
| MounjaroTirzepatide | 27 | $39,433 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $33,043 |
| OzempicSemaglutide | 29 | $31,163 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $26,921 |
| TrulicityDulaglutide | 24 | $26,111 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $11,175 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $10,839 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $5,217 |
| Novolog FlexpenInsulin Aspart | 16 | $2,629 |
| SynthroidLevothyroxine Sodium | 23 | $1,893 |
| Hydrocortisone | 39 | $1,671 |
| Levothyroxine Sodium | 140 | $1,228 |
| Methimazole | 59 | $607 |
| Liothyronine Sodium | 11 | $226 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Tacoma
- Ronald GrafTacoma$478K
- Gabriela Loperena OropezaTacoma$12K
- Ayesha JameelTacoma$9K
- Rebecca OverTacoma$6K
- Rani KulkarniTacoma$3K
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.